Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, wi...

Fuld beskrivelse

Bibliografiske detaljer

Udgivet i:	J Virol
Principais autores:	Jin, Xia, Ramanathan, Jr., Murugappan, Barsoum, Shady, Deschenes, Geoffrey R., Ba, Lei, Binley, James, Schiller, Daryl, Bauer, Daniel E., Chen, Donald C., Hurley, Arlene, Gebuhrer, Lucette, El Habib, Raphaelle, Caudrelier, Pierre, Klein, Michel, Zhang, Linqi, Ho, David D., Markowitz, Martin
Format:	Artigo
Sprog:	Inglês
Udgivet:	American Society for Microbiology (ASM) 2002
Fag:	Vaccines and Antiviral Agents
Online adgang:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC135946/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11836398/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.76.5.2206-2216.2002
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!